You can buy or sell ALRN and other stocks, options, ETFs, and crypto commission-free!
Aileron Therapeutics, Inc. Common Stock, also called Aileron Therapeutics, is a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel class of therapeutics for the treatment of cancer and other diseases. Read More It focuses on its lead products candidate, ALRN-6924 which is a cell-permeating peptide that disrupts the interaction of p53 suppressors MDM2 and MDMX with tumor suppressor p53 to reactivate tumor suppression in non-mutant, or wild-type, p53 cancers. The company was founded by Gregory L. Verdine, Rosana Kapeller, Huw M. Nash, Joseph A. Yanchik III, and Loren David Walensky in June 2005 and is headquartered in Cambridge, MA. The listed name for ALRN is Aileron Therapeutics, Inc. Common Stock.
52 Week High
52 Week Low
— per share
Expected Nov 5, After Hours